Ioannis K Karalis
Overview
Explore the profile of Ioannis K Karalis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karalis I, Bergheanu S, Wolterbeek R, Dallinga-Thie G, Hattori H, Van Tol A, et al.
Curr Med Res Opin
. 2010 Aug;
26(10):2301-13.
PMID: 20731529
Unlabelled: This paper contains detailed results of a sub-population of the prospective randomized RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Objective: Statin treatment results in...
2.
Skalidis E, Hamilos M, Karalis I, Chlouverakis G, Kochiadakis G, Vardas P
J Am Coll Cardiol
. 2008 May;
51(21):2053-7.
PMID: 18498961
Objectives: The purpose of this study was to assess atrial myocardial perfusion in patients with lone recurrent atrial fibrillation (LRAF). Background: Although acute atrial ischemia has been implicated in the...
3.
Risk factors for ischaemic heart disease in a Cretan rural population: a twelve year follow-up study
Karalis I, Alegakis A, Kafatos A, Koutis A, Vardas P, Lionis C
BMC Public Health
. 2007 Dec;
7:351.
PMID: 18088432
Background: Crete has been of great epidemiological interest ever since the publication of the Seven Countries Study. In 1988 a well-defined area of rural Crete was studied, with only scarce...
4.
Kontaraki J, Parthenakis F, Patrianakos A, Karalis I, Vardas P
Cardiovasc Pathol
. 2007 Nov;
16(6):329-35.
PMID: 18005871
Background: Early cardiac marker genes, such as cardiac-specific homeobox (Csx/Nkx2.5), myocardin, homeodomain only protein, GATA4, and myocyte enhancer factor 2C, are thought to participate in cardiomyocyte differentiation and to contribute...
5.
Chrysostomakis S, Karalis I, Simantirakis E, Koutsopoulos A, Mavrakis H, Chlouverakis G, et al.
Cardiovasc Drugs Ther
. 2007 Oct;
21(5):357-65.
PMID: 17909956
Background: Using a goat animal model, we tested the hypothesis that angiotensin-II inhibition reduces fibrotic degeneration of both the atrial and ventricular myocardium as well as AF induction susceptibility. Methods:...
6.
Parthenakis F, Patrianakos A, Skalidis E, Diakakis G, Zacharis E, Chlouverakis G, et al.
Int J Cardiol
. 2006 Oct;
118(2):206-14.
PMID: 17027102
Objectives: To assess atrial fibrillation (AF) associated differences in proinflammatory cytokines, natriuretic peptide levels and exercise capacity in patients with heart failure (HF) secondary to non-ischemic dilated cardiomyopathy (NIDC). Methods:...
7.
Chrysostomakis S, Simantirakis E, Schiza S, Karalis I, Klapsinos N, Siafakas N, et al.
Hellenic J Cardiol
. 2006 Mar;
47(1):13-20.
PMID: 16532711
Introduction: Sleep apnoea, which constitutes a major social problem because of its high prevalence and its emerging association with cardiovascular morbidity and mortality, is known to affect autonomic nervous system...